Press release from Davidson Kempner regarding Qiagen

LONDON, Aug. 13, 2020 /PRNewswire/ -- Davidson Kempner is pleased that the majority of investors have rejected the wholly inadequate offer made by Thermo Fisher Scientific. The low acceptance level of 47.02% is a clear signal that there is widespread confidence in the long-term prospects of Qiagen N.V. ("the Company").

As the Company's second largest investor, we are committed to realizing the significant underlying value that we see in the Company. In particular, we will look to:

-- Improve the quality of engagement between the Company and its investors
and rebuild trust with all of its stakeholders;
-- Refocus the strategy towards a high growth business with a disciplined
capital allocation framework; and
-- Fully capitalise on the exciting opportunities available to the Company,
including the tailwinds of the COVID-19 pandemic.
We look forward to presenting our thoughts on all the above topics in the near future.

For media enquiries:
Andrew Honnor, Rob White, Fanni Bodri
Email: []
Tel.: +44 (0)20 7952 2000

PR Newswire

Dit persbericht is via ANP Pers Support naar internationale (vak en online) media gestuurd. Heb je nieuws voor buitenlandse journalisten? Bekijk dan onze mogelijkheden of neem contact met ons op.

Verstuur nu éénmalig een persbericht

Verstuur persberichten en beeldmateriaal naar redacties in binnen- en buitenland. Via het ANP-net, het internationale medianetwerk van PR Newswire of met een perslijst op maat.

Direct persbericht versturen
070 - 41 41 234